# A weight-loss plateau on tirzepatide: what to review

A plateau needs a treatment review, not a verdict about willpower. Start with the timeline, benefits, side effects, and recent changes.

Canonical: https://velri.co/blog/tirzepatide-plateau-behavior-vs-biology-provider-reads
Publisher: Velri (https://velri.co/about)
Published: 2026-07-13
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A weight-loss plateau can occur while someone continues taking tirzepatide as prescribed. In an exploratory analysis of two trials, most selected participants eventually reached the researchers’ definition of a plateau, even though all had lost at least 5% of their starting weight.[3]

That makes a pause in further loss different from evidence that treatment never helped.

## What the research called a plateau

The analysis used data from SURMOUNT-1 and SURMOUNT-4. It included participants who adhered to treatment and reached the specified weight-loss threshold. Researchers defined a plateau as less than 5% weight change over a 12-week interval and the intervals afterward.[3]

This is broader than a few unchanged morning weigh-ins. It also describes a selected group, not everyone who starts tirzepatide. The analysis explored associations with the time to plateau; it did not establish the cause of one person’s stalled weight.[3]

## Read the whole treatment course

The useful comparison includes starting weight, earlier losses and the duration of the current trend. Missed treatment, supply interruptions, appetite changes and daily circumstances can be recorded without assuming that any one detail explains everything.

Weight-management decisions consider health history, benefit and tolerability. Maintaining an earlier reduction may be part of the benefit being assessed.[2]

## Symptoms still matter

Tirzepatide can cause nausea, diarrhea, vomiting, constipation and abdominal pain.[1] Difficulty eating or drinking belongs in the review even when the scale is stable.

A plateau does not dictate an automatic change in prescription. It creates a specific question: what benefit is being maintained, what remains to be addressed, and how does that balance compare with the treatment’s burdens? That assessment is more informative than assigning the result to either behavior or biology from the weight trend alone.[2]

## Sources
[1] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[2] Prescription Medications to Treat Overweight & Obesity - NIDDK. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[3] Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. (2025). https://pubmed.ncbi.nlm.nih.gov/39800653/

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support